ONCOLOGY: KRAS provides maintenance for pancreatic cancer The outlook for individuals diagnosed with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (PDA), is very poor; the average time of survival after diagnosis is less than 6 months. New therapeutic approaches are therefore much needed. By developing and studying two new mouse models of pancreatic cancer, a team of researchers led by Marina Pasca di Magliano, at the University of Michigan, Ann Arbor, has now identified potential new targets for treating individuals with this terminal condition...
More...
More...